The Gut Microbiome in Adult Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— MICROMS5Y  

Official title:

Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis I

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04929145
• Other study ID #: MICROMS5Y
• Status: Completed
• Start date: October 2, 2013
• Est. completion date: April 2020

Study information

• Verified date: July 2021
• Source: National MS Center Melsbroek
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to assess the following research questions:

1. Map and benchmark the gut microbiome of patients with RRMS, and PPMS versus matched healthy controls

2. Determine whether RRMS or PPMS have a unique bias for a gut microbiome classification recently characterized.

3. Search for relationship with inflammation, amino acid plasma levels, heart rate variability (vagus nerve tone) and hair cortisol as a biological marker of chronic stress

4. Determine whether the gut microbiome is different in MS patients during a relapse.

5. Determine whether the gut microbiome remains stable after 3 months

Description:

This study is a prospective multi-center cohort study (University Hospital Brussels, National Multiple Sclerosis Center Melsbroek). This is an exploratory study and there is no specific outcome on which a power calculation can be made. We will include different subgroups of patients with MS: stable non-benign RRMS, PPMS, benign MS [Benign MS is defined as RRMS with an EDSS ≤ 3, 15 years after disease onset], RRMS during a relapse (before the administration of corticosteroids) [Relapses are defined as the development of new or recurrent neurologic symptoms not associated with fever or infection or change in medication, lasting at least 24 hours, and accompanied by new, objective neurologic findings]. Age and sex matched healthy controls will be included as well. All participants will provide a faecal, hair, and blood sample twice (baseline and after 3 months). Patients will be assessed clinically at baseline, 3 months after baseline, and approximately 1, 2, 4.5 years after baseline.

The results of this study have the potential to identify novel simple strategies to strengthen or alter the microbiome ecosystem and strengthen the overall treatment process. In case of a positive result, this would form the basis for a follow-up study on medical modulation of the microbiome with the aim of finding new treatment options for MS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 152
• Est. completion date: April 2020
• Est. primary completion date: September 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent.

2. RRMS or PPMS, as defined by the McDonald criteria.

3. Ages 18-65 years.

4. EDSS < 7

5. Treatment with IFN-beta

Exclusion Criteria:

1. SPMS without relapses during the past year at screening.

2. Use of high dose systemic steroids within the last 2 months.

3. Gastrointestinal disease, such as inflammatory bowel disease

4. Use of antibiotics within the last 4 weeks.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Brussel	Jette	Brussel-Hoofdstedelijk-Gewest
Belgium	Nationaal Multiple Sclerose Centrum Melsbroek	Melsbroek	Vlaams-Brabant

Sponsors (1)

Lead Sponsor	Collaborator
National MS Center Melsbroek

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sustained disability worsening	Sustained disability worsening will be assessed using the Expanded Disability Status Scale (EDSS)-Plus outcome. This is a composite measure that assesses disability worsening based on changes of the EDSS score (difference of at least 1.5;1.0;0.5 depending on baseline score), the timed 25-foot walk (T25FW) score (>=20%), and the 9-hole peg test (9-HPT) score (>=20%). If worsening of any of these measures occurred, the patient has clinically deteriorated according to the EDSS-Plus outcome.	5 years
Secondary	Clinical evidence for active disease	Time to first relapse (after baseline) will be reported for all patients. Annualized relapse frequency	5 years